Aquestive resubmits Anaphylm application to FDA after January rejection
AI Summary- Aquestive Therapeutics resubmitted Anaphylm’s New Drug Application to the FDA.
- January 30, 2026: FDA requested confirmatory pharmacokinetic and human factors studies.
- Aquestive completed revised-packaging testing and a healthy-volunteer pharmacokinetic trial.